Trial Profile
A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Clazakizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb; Vitaeris
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 07 May 2015 According to Alder BioPharmaceuticals media release, data will be presented at a future rheumatology society meeting.
- 05 May 2015 Results published in an Alder Biopharmaceuticals media release.